Victor Gura1,2, Matthew B Rivara3, Scott Bieber3, Raj Munshi3,4, Nancy Colobong Smith3,5, Lori Linke3, John Kundzins3, Masoud Beizai6, Carlos Ezon6, Larry Kessler3,7, Jonathan Himmelfarb3. 1. Cedars-Sinai Medical Center, Los Angeles, California, USA. 2. David Geffen School of Medicine at UCLA, UCLA, Los Angeles, California, USA. 3. Kidney Research Institute, Division of Nephrology, University of Washington, Seattle, Washington, USA. 4. Division of Nephrology, Department of Pediatrics, Seattle Children's Hospital and University of Washington, Seattle, Washington, USA. 5. University of Washington Medical Center, Seattle, Washington, USA. 6. Blood Purification Technologies Inc., Beverly Hills, California, USA. 7. Department of Health Services, School of Public Health, University of Washington, Seattle, Washington, USA.
Abstract
BACKGROUND: Stationary hemodialysis machines hinder mobility and limit activities of daily life during dialysis treatments. New hemodialysis technologies are needed to improve patient autonomy and enhance quality of life. METHODS: We conducted a FDA-approved human trial of a wearable artificial kidney, a miniaturized, wearable hemodialysis machine, based on dialysate-regenerating sorbent technology. We aimed to determine the efficacy of the wearable artificial kidney in achieving solute, electrolyte, and volume homeostasis in up to 10 subjects over 24 hours. RESULTS: During the study, all subjects remained hemodynamically stable, and there were no serious adverse events. Serum electrolytes and hemoglobin remained stable over the treatment period for all subjects. Fluid removal was consistent with prescribed ultrafiltration rates. Mean blood flow was 42 ± 24 ml/min, and mean dialysate flow was 43 ± 20 ml/min. Mean urea, creatinine, and phosphorus clearances over 24 hours were 17 ± 10, 16 ± 8, and 15 ± 9 ml/min, respectively. Mean β2-microglobulin clearance was 5 ± 4 ml/min. Of 7 enrolled subjects, 5 completed the planned 24 hours of study treatment. The trial was stopped after the seventh subject due to device-related technical problems, including excessive carbon dioxide bubbles in the dialysate circuit and variable blood and dialysate flows. CONCLUSION: Treatment with the wearable artificial kidney was well tolerated and resulted in effective uremic solute clearance and maintenance of electrolyte and fluid homeostasis. These results serve as proof of concept that, after redesign to overcome observed technical problems, a wearable artificial kidney can be developed as a viable novel alternative dialysis technology. TRIAL REGISTRATION: ClinicalTrials.gov NCT02280005. FUNDING: The Wearable Artificial Kidney Foundation and Blood Purification Technologies Inc.
BACKGROUND: Stationary hemodialysis machines hinder mobility and limit activities of daily life during dialysis treatments. New hemodialysis technologies are needed to improve patient autonomy and enhance quality of life. METHODS: We conducted a FDA-approved human trial of a wearable artificial kidney, a miniaturized, wearable hemodialysis machine, based on dialysate-regenerating sorbent technology. We aimed to determine the efficacy of the wearable artificial kidney in achieving solute, electrolyte, and volume homeostasis in up to 10 subjects over 24 hours. RESULTS: During the study, all subjects remained hemodynamically stable, and there were no serious adverse events. Serum electrolytes and hemoglobin remained stable over the treatment period for all subjects. Fluid removal was consistent with prescribed ultrafiltration rates. Mean blood flow was 42 ± 24 ml/min, and mean dialysate flow was 43 ± 20 ml/min. Mean urea, creatinine, and phosphorus clearances over 24 hours were 17 ± 10, 16 ± 8, and 15 ± 9 ml/min, respectively. Mean β2-microglobulin clearance was 5 ± 4 ml/min. Of 7 enrolled subjects, 5 completed the planned 24 hours of study treatment. The trial was stopped after the seventh subject due to device-related technical problems, including excessive carbon dioxide bubbles in the dialysate circuit and variable blood and dialysate flows. CONCLUSION: Treatment with the wearable artificial kidney was well tolerated and resulted in effective uremic solute clearance and maintenance of electrolyte and fluid homeostasis. These results serve as proof of concept that, after redesign to overcome observed technical problems, a wearable artificial kidney can be developed as a viable novel alternative dialysis technology. TRIAL REGISTRATION: ClinicalTrials.gov NCT02280005. FUNDING: The Wearable Artificial Kidney Foundation and Blood Purification Technologies Inc.
Authors: Nazanin Noori; Kamyar Kalantar-Zadeh; Csaba P Kovesdy; Sameer B Murali; Rachelle Bross; Allen R Nissenson; Joel D Kopple Journal: Am J Kidney Dis Date: 2010-06-30 Impact factor: 8.860
Authors: Rachael L Morton; Paul Snelling; Angela C Webster; John Rose; Rosemary Masterson; David W Johnson; Kirsten Howard Journal: Am J Kidney Dis Date: 2012-03-13 Impact factor: 8.860
Authors: M J Blumenkrantz; A Gordon; M Roberts; A J Lewin; E A Pecker; J K Moran; J W Coburn; M H Maxwell Journal: Artif Organs Date: 1979-08 Impact factor: 3.094
Authors: Kirsten L Johansen; Rebecca Zhang; Yijian Huang; Shu-Cheng Chen; Christopher R Blagg; Alexander S Goldfarb-Rumyantzev; Chistopher D Hoy; Robert S Lockridge; Brent W Miller; Paul W Eggers; Nancy G Kutner Journal: Kidney Int Date: 2009-08-19 Impact factor: 10.612
Authors: J Craig Longenecker; Josef Coresh; Neil R Powe; Andrew S Levey; Nancy E Fink; Alice Martin; Michael J Klag Journal: J Am Soc Nephrol Date: 2002-07 Impact factor: 10.121
Authors: Robert M Lindsay; Paul A Heidenheim; Gihad Nesrallah; Amit X Garg; Rita Suri Journal: Clin J Am Soc Nephrol Date: 2006-07-06 Impact factor: 8.237
Authors: William R Clark; Mauro Neri; Francesco Garzotto; Zaccaria Ricci; Stuart L Goldstein; Xiaoqiang Ding; Jiarui Xu; Claudio Ronco Journal: Crit Care Date: 2017-04-11 Impact factor: 9.097